Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trials

March 31, 2026Communications MedicineOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to assess the effectiveness, immunogenicity, and safety of monovalent and bivalent SARS-CoV-2 vaccines.
Conducted two randomized, active-comparator trials.
Evaluated monovalent DS-5670a and bivalent DS-5670a/b vaccines.
Compared effectiveness and safety against other vaccines.
Ensured a non-inferiority design to validate results.
Both vaccine types show strong immunogenicity against SARS-CoV-2.
Safety profiles appear favorable with minimal adverse effects.
Monovalent and bivalent vaccines are effective in generating immune responses.

We only have this paper's title and publication details.

Study evaluate safety and immunogenicity of two SARS-CoV-2 vaccines, suggesting effective options for future variants.

This platform can be utilized to produce new vaccines against future SARS-CoV-2 variants.

No takes yet. Share an insight, caveat, or question.

Hamada et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share